Globus Medical Stock Forecast, Price & News

Globus Medical (NYSE:GMED) Frequently Asked Questions

Is Globus Medical a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Globus Medical stock.
View analyst ratings for Globus Medical or view top-rated stocks.

What stocks does MarketBeat like better than Globus Medical?

Wall Street analysts have given Globus Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Globus Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Globus Medical?

Globus Medical saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 1,160,000 shares, a drop of 17.1% from the July 29th total of 1,400,000 shares. Based on an average daily trading volume, of 393,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.5% of the company's shares are short sold.
View Globus Medical's Short Interest.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Globus Medical.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its quarterly earnings data on Wednesday, August, 4th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.12. The medical device company had revenue of $251.02 million for the quarter, compared to analysts' expectations of $225.50 million. Globus Medical had a trailing twelve-month return on equity of 14.10% and a net margin of 19.83%. The company's revenue was up 68.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.07 earnings per share.
View Globus Medical's earnings history.

How has Globus Medical's stock price been impacted by COVID-19 (Coronavirus)?

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GMED stock has increased by 111.4% and is now trading at $80.44.
View which stocks have been most impacted by COVID-19.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share (EPS) guidance of $2.000-$2.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.890. The company issued revenue guidance of $950 million-$950 million, compared to the consensus revenue estimate of $926.78 million.

What price target have analysts set for GMED?

11 brokerages have issued 1 year price objectives for Globus Medical's stock. Their forecasts range from $56.00 to $96.00. On average, they anticipate Globus Medical's share price to reach $82.18 in the next year. This suggests a possible upside of 2.2% from the stock's current price.
View analysts' price targets for Globus Medical or view top-rated stocks among Wall Street analysts.

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:

• David M. Demski, President, Chief Executive Officer & Director (LinkedIn Profile)
• Keith W. Pfeil, Senior VP, Chief Financial & Accounting Officer (LinkedIn Profile)
• Daniel T. Scavilla, Chief Commercial Officer & Executive VP
• Kelly G. Huller, Secretary, Senior VP & General Counsel
• Brett A. Murphy, Group President-Commercial Operations

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Globus Medical's key competitors?

Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of GMED's competitors.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), The Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.32%), Vanguard Group Inc. (7.23%), State Street Corp (2.11%), Champlain Investment Partners LLC (1.51%), AXA S.A. (1.47%) and Kayne Anderson Rudnick Investment Management LLC (1.26%). Company insiders that own Globus Medical stock include Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends for Globus Medical.

Which institutional investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Van Berkom & Associates Inc., Nuance Investments LLC, BlackRock Inc., Balyasny Asset Management LLC, Invesco Ltd., Banque Pictet & Cie SA, Citigroup Inc., and Geode Capital Management LLC. Company insiders that have sold Globus Medical company stock in the last year include Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, and Kelly Huller.
View insider buying and selling activity for Globus Medical or view top insider-selling stocks.

Which institutional investors are buying Globus Medical stock?

GMED stock was bought by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Integral Health Asset Management LLC, State Street Corp, Vanguard Group Inc., FMR LLC, Point72 Asset Management L.P., Marathon Asset Management LLP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Globus Medical or or view top insider-buying stocks.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $80.44.

How much money does Globus Medical make?

Globus Medical has a market capitalization of $8.12 billion and generates $789.04 million in revenue each year. The medical device company earns $102.29 million in net income (profit) each year or $1.44 on an earnings per share basis.

How many employees does Globus Medical have?

Globus Medical employs 2,200 workers across the globe.

What is Globus Medical's official website?

The official website for Globus Medical is www.globusmedical.com.

Where are Globus Medical's headquarters?

Globus Medical is headquartered at 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at (610) 930-1800 or via email at [email protected].